Posted on February 15, 2021 by Sitemaster
We saw recently (see this link) that of chemotherapeutic and hormonal medicines for treatment of metastatic castration-resistant prostate cancer (mCRPC), Jevtana (cabazitaxel) is the preferred third-line treatment after Taxotere (docetaxel) and Zytiga (abiraterone acetate) or Xtandi (enzalutamide). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, Jevtana, Lu-177-PSMA-617, mCRPC | 3 Comments »
Posted on September 19, 2019 by Sitemaster
A newly published article in Lancet Oncology has suggested that “taxane–platinum combinations have a clinically beneficial role in advanced prostate cancer”. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, carboplatin, castration-resistant, mCRPC, metastatic | 2 Comments »
Posted on October 25, 2018 by Sitemaster
A report on the UroToday web site has addressed a presentation given this week at the ESMO 2018 Congress in Munich, Germany, that is relevant to the potential value of taking a statin while you are being treated for very late stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, data, interpretation, outcome, statin | 1 Comment »
Posted on September 15, 2017 by Sitemaster
Yesterday, in line with previously reported data, the US Food and Drug Administration (FDA) approved the used of a 20 mg/ml dose of cabazitaxel (Jevtana) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, dose, Jevtana, lower, mCRPC | Leave a comment »
Posted on September 12, 2017 by Sitemaster
In another presentation from the ESMO meeting in Madrid, Spain, Fizazi et al. presented data from the randomized CABA-DOC trial exploring patients’ preferences for either docetaxel or cabazitaxel as a first-line form of chemotherapy. … READ MORE …
Filed under: Management, Treatment | Tagged: cabazitaxel, chemotherapy, choice, docetaxel, preference, taxane | 2 Comments »
Posted on August 25, 2017 by Sitemaster
The results of two recent, large clinical trials may have some impact on the clinical use of cabazitaxel (Jevtana) in the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, docetaxel, dosing, Jevtana, outcome, Taxotere | 3 Comments »
Posted on October 11, 2016 by Sitemaster
In August we had reported on an announcement by OncoGenex Pharmaceuticals that, in the Phase III AFFINITY trial, the combination of custirsen + cabazitaxel (Jevtana) + prednisone had no significant impact on overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC) who had already received first-line chemotherapy by comparison with cabazitaxel + prednisone alone. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: AFFINITY, cabazitaxel, custirsen, outcome, Phase III, trial | Leave a comment »
Posted on April 22, 2016 by Sitemaster
According to news reports this morning, the National Institute for Health and Care Excellence (NICE) in England has changed its tune about covering cabazitaxel (Jevtana) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ NORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, England, NICE | Leave a comment »
Posted on March 21, 2016 by Sitemaster
Drugs like docetaxel and cabazitaxel (taxanes) are among the most active forms of treatment in the management of men with metastatic, castration-resistant prostate cancer (mCRPC), but they don’t work for everyone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cabazitaxel, docetaxel, expression, gene, taxane, TMPRSS2-ERG | Leave a comment »
Posted on September 8, 2015 by Sitemaster
As reported in a wide spectrum of media over the past few days (see here for example), on Friday last week the National Health Service announced that it would no longer cover the costs associated with use of cabazitaxel (Jevtana) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC) through the UK’s Cancer Drugs Fund — effective as of November 1, 2015. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: access, cabazitaxel, castration-resistant, cost, Jevtana, mCRPC, metastatic, UK | 8 Comments »
Posted on August 14, 2015 by Sitemaster
A research team working just down the street here in Philadelphia thinks cabazitaxel (Jevtana) may have expanded potential in treatment of some men with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, castration-resistant, chemotherapy, CRPC | 10 Comments »
Posted on November 14, 2014 by Sitemaster
A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, cabazitaxel, outcome, risk, sequencing, Treatment | Leave a comment »
Posted on February 14, 2013 by Sitemaster
A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, aflibercept, ARN-509, cabazitaxel, cediranib, dasatinib, enzalutamide, radium-223, sipuleucel-T | 6 Comments »
Posted on January 14, 2013 by Sitemaster
A new article on the Medcape Oncology web site discusses progress in the treatment of metastatic, catsration-resistant prostate cancer (mCRPC) and the specific relationship between risk for brain metastasis and the extension of overall survival. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, brain, cabazitaxel, castration-resistant, docetaxel, metastasis, metastatic, survival | Leave a comment »
Posted on September 25, 2012 by Sitemaster
Whether a man is initially diagnosed with metastatic prostate cancer or progresses to have metastatic disease over time (after failure of standard first-line therapies), sooner or later they are all going to need — in consultation with their doctors — to decide on “the best” way to manage their progressive disease through sequential or concurrent use of a number of recently approved agents (always assuming that cost and access are not determining factors). … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, advanced, cabazitaxel, docetaxel, enzalutamide, metastatic, outcome, sequence, sipuleucel-T | Leave a comment »